Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225 PSMA-R2

A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 225Ac-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by a cytotoxic dose of alpha radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.
Synonym:[225Ac]Ac-PSMA-R2
225Ac-labeled PSMA-R2
225Ac-PSMA-R2
225AcPSMA-R2
Ac225-PSMA-R2
actinium (225Ac) PSMA-R2
actinium-225 PSMA-R2
Search NCI's Drug Dictionary